As investors fret over the modest uptake of the controversial Sarepta Therapeutics drug for Duchenne muscular dystrophy, a new survey suggests the treatment may soon be more widely prescribed, although the findings come with a caveat.
About half of 100 neurologists reported they would prescribe the drug to at least 80 percent of their eligible patients and only 10 percent of the physicians indicated they would narrowly restrict its use, according to RBC Capital Markets analyst Simos Simeonidis, who commissioned the poll.
About the Author Reprints
